Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology (Q39629610)

13 September 2017

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology (English)

1 reference

13 September 2017

0 references

R Bateman

7

0 references

John C. Morris

13

object named as

J Morris

1 reference

13 September 2017

12

M Mintun

1 reference

13 September 2017

14

R Petersen

1 reference

13 September 2017

23

P Aisen

1 reference

13 September 2017

B Vellas

1

1 reference

13 September 2017

H Hampel

2

1 reference

13 September 2017

M E Rougé-Bugat

3

1 reference

13 September 2017

M Grundman

4

1 reference

13 September 2017

S Andrieu

5

1 reference

13 September 2017

S Abu-Shakra

6

1 reference

13 September 2017

R Berman

8

1 reference

13 September 2017

R Black

9

1 reference

13 September 2017

M Carrillo

10

1 reference

13 September 2017

M Donohue

11

1 reference

13 September 2017

R G Thomas

15

1 reference

13 September 2017

J Suhy

16

1 reference

13 September 2017

L Schneider

17

1 reference

13 September 2017

L Seely

18

1 reference

13 September 2017

P Tariot

19

1 reference

13 September 2017

J Touchon

20

1 reference

13 September 2017

M Weiner

21

1 reference

13 September 2017

C Sampaio

22

1 reference

13 September 2017

Task Force Participants

24

1 reference

13 September 2017

1 April 2012

1 reference

The Journal of Nutrition, Health and Aging

13 September 2017

1 reference

13 September 2017

16

1 reference

13 September 2017

4

1 reference

13 September 2017

339-345

1 reference

https://scigraph.springernature.com/pub.10.1007/s12603-012-0044-x

13 September 2017

0 references

cites work

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." A national registry to identify a cohort for Alzheimer's disease prevention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Designing a large prevention trial: statistical issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

IAGG workshop: health promotion program on prevention of late onset dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Dementia prevention: methodological explanations for inconsistent results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Biomarkers for Alzheimer's disease therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-012-0044-X

Recruitment methods for United States Alzheimer disease prevention trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22499454

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22499454

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12603-012-0044-X

1 reference

13 September 2017

1 reference